GLP-1 Market
LLY $1137.82 ▲ +0.2% NVO $41.71 ▼ -1.9% PFE $27.46 ▼ -0.3% VKTX $29.52 ▼ -1.4% KLRA $12.70 ▼ -5.6% GPCR $35.50 ▼ -8.9% RHHBY $55.15 ▲ +0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Palbociclib

Company
Hoffmann-La Roche
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
71 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

71 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for Palbociclib and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT02896335

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

    Not yet reported Massachusetts General Hospital 45 participants Est. completion 2029-09-01 2 sites Stand-alone
    Other conditions: Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain Metastases
    View official trial listing →
  • Recruiting NCT NCT02925234

    The Drug Rediscovery Protocol (DRUP Trial)

    Not yet reported The Netherlands Cancer Institute 1550 participants Est. completion 2027-12 36 sites Stand-alone
    Other conditions: Cancer, Tumors, Neoplasm, Neoplasia
    View official trial listing →
  • Recruiting NCT NCT03297606

    Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

    Not yet reported Canadian Cancer Trials Group 720 participants Est. completion 2027-01-31 10 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT03424005

    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

    Not yet reported, Not yet reported Hoffmann-La Roche 1132 participants Est. completion 2030-09-30 53 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT03454035

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

    Not yet reported UNC Lineberger Comprehensive Cancer Center 45 participants Est. completion 2028-02-03 1 site Stand-alone
    Other conditions: Tumor, Solid, Pancreatic Cancer, Melanoma
    View official trial listing →
  • Recruiting NCT NCT04025541

    Analysis of Circulating Tumor Markers in Blood

    Not yet reported Institut du Cancer de Montpellier - Val d'Aurelle 992 participants Est. completion 2029-05-29 2 sites
    Other conditions: Cancer, Breast Cancer, Sarcoma, Lung Cancers, Glioma, Colon Cancer
    View official trial listing →
  • Recruiting NCT NCT04423185

    PLATFORM Study of Precision Medicine for Rare Tumors

    Not yet reported Cancer Institute and Hospital, Chinese Academy of Medical Sciences 770 participants Est. completion 2028-07-01 1 site Stand-alone
    Other conditions: Rare Tumor
    View official trial listing →
  • Recruiting NCT NCT04563507

    Combined Immunotherapies in Metastatic ER+ Breast Cancer

    Not yet reported Weill Medical College of Cornell University 102 participants Est. completion 2028-10-31 3 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04606446

    Study of PF-07248144 in Advanced or Metastatic Solid Tumors

    Not yet reported Pfizer 320 participants Est. completion 2029-08-10 44 sites Stand-alone
    Other conditions: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT04654208

    Swedish Ibrance Registries Insights (SIRI)

    Pfizer 1500 participants Est. completion 2026-05-31 1 site
    Other conditions: Malignant Neoplasm of Breast
    View official trial listing →
  • Recruiting NCT NCT04660435

    To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer

    Fondazione Sandro Pitigliani 150 participants Est. completion 2030-12-01 1 site
    Other conditions: Metastatic Breast Cancer, ER Positive Breast Cancer, HER2-negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04693468

    Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

    Not yet reported M.D. Anderson Cancer Center 111 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
    View official trial listing →
  • Recruiting NCT NCT04802759

    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

    Not yet reported, Not yet reported Hoffmann-La Roche 316 participants Est. completion 2029-05-30 32 sites Stand-alone
    Other conditions: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04819243

    PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study

    Not yet reported Samsung Medical Center 178 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Premenopausal HR+/HER2- Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04841148

    Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

    Not yet reported Abramson Cancer Center at Penn Medicine 96 participants Est. completion 2028-05 7 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04925856

    Immunomonitoring of Breast Cancer Patients During Systemic Treatment

    Not yet reported Centre Georges Francois Leclerc 150 participants Est. completion 2030-05-26 2 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04966481

    Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

    Not yet reported Washington University School of Medicine 81 participants Est. completion 2028-02-28 5 sites Stand-alone
    Other conditions: HPV-unrelated Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Recruiting NCT NCT04985266

    A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

    Not yet reported Royal Marsden NHS Foundation Trust 1100 participants Est. completion 2030-09-01 49 sites Stand-alone
    Other conditions: ER+ Breast Cancer, HER2-negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05190094

    Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.

    Not yet reported International Cancer Research Group, United Arab Emirates 80 participants Est. completion 2026-06 7 sites Stand-alone
    Other conditions: Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05216432

    First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    Not yet reported Relay Therapeutics, Inc. 930 participants Est. completion 2027-04-30 37 sites Stand-alone
    Other conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor
    View official trial listing →
  • Recruiting NCT NCT05432518

    Pilot Trial for Treatment of Recurrent Glioblastoma

    Not yet reported AHS Cancer Control Alberta 10 participants Est. completion 2027-12-01 1 site Stand-alone
    Other conditions: Glioblastoma, Recurrent Disease, Recurrent Glioblastoma
    View official trial listing →
  • Recruiting NCT NCT05564377

    Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    Not yet reported National Cancer Institute (NCI) 2900 participants Est. completion 2030-07-01 482 sites Stand-alone
    Other conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
    View official trial listing →
  • Recruiting NCT NCT05627232

    Tazemetostat and Palbociclib With CPX-351for R/R AML

    Not yet reported Thomas Jefferson University 24 participants Est. completion 2029-01 1 site Stand-alone
    Other conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT05665361

    Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)

    Not yet reported, Not yet reported National Cancer Institute (NCI) 100 participants Est. completion 2027-06-01 1 site Stand-alone
    Other conditions: Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc)
    View official trial listing →
  • Recruiting NCT NCT05683418

    A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

    Not yet reported Totus Medicines 241 participants Est. completion 2027-12 18 sites Stand-alone
    Other conditions: HR+/HER2-negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05696626

    Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    Not yet reported LeonaBio 600 participants Est. completion 2028-04 224 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05725200

    Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

    Not yet reported Oslo University Hospital 40 participants Est. completion 2040-12-31 1 site Stand-alone
    Other conditions: Metastatic Colorectal Cancer
    View official trial listing →
  • Recruiting NCT NCT05766410

    A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC

    Not yet reported National Taiwan University Hospital 60 participants Est. completion 2026-09-30 2 sites Stand-alone
    Other conditions: Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Therapy
    View official trial listing →
  • Recruiting NCT NCT05768139

    First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

    Not yet reported, Not yet reported Eli Lilly and Company 880 participants Est. completion 2030-07 65 sites Stand-alone
    Other conditions: Breast Cancer, Solid Tumors, Adult
    View official trial listing →
  • Recruiting NCT NCT05867251

    Study of AVZO-021 in Patients With Advanced Solid Tumors

    Not yet reported, Not yet reported Avenzo Therapeutics, Inc. 430 participants Est. completion 2030-01-31 13 sites Stand-alone
    Other conditions: Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, TNBC - Triple-Negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT05953350

    A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i

    Not yet reported, Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 29 participants Est. completion 2024-12-31 1 site Stand-alone
    Other conditions: Inhibition of Autophagy Synergizes Anti-tumor Effect
    View official trial listing →
  • Recruiting NCT NCT06044623

    Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients

    Not yet reported Region Örebro County 495 participants Est. completion 2029-05-31 12 sites Stand-alone
    Other conditions: Metastatic Breast Cancer, Advanced Breast Cancer, Quality of Life, Toxicity, Older Patients
    View official trial listing →
  • Recruiting NCT NCT06062498

    Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

    Not yet reported Northwestern University 174 participants Est. completion 2029-07-01 3 sites Stand-alone
    Other conditions: Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv, Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06113809

    Palbociclib and Pembrolizumab in Sarcoma

    Not yet reported John Rieth 8 participants Est. completion 2028-07 1 site Stand-alone
    Other conditions: Sarcoma
    View official trial listing →
  • Recruiting NCT NCT06126276

    Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

    Not yet reported National Cancer Institute (NCI) 70 participants Est. completion 2027-02-20 193 sites Stand-alone
    Other conditions: Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm
    View official trial listing →
  • Recruiting NCT NCT06145308

    Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

    Not yet reported Peking Union Medical College 39 participants Est. completion 2028-07-10 2 sites Stand-alone
    Other conditions: Salivary Gland Carcinoma, Precision Therapy
    View official trial listing →
  • Recruiting NCT NCT06171360

    A Study of the Gut Microbiome in Hormone Receptor-positive HER2-negative Breast Cancer Treated With CDK4/6 Inhibitors

    Cliniques universitaires Saint-Luc- Université Catholique de Louvain 100 participants Est. completion 2030-12-31 3 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06176534

    Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

    Not yet reported Henan Cancer Hospital 240 participants Est. completion 2026-12-20 1 site
    Other conditions: Advanced Breast Cancer, Treatment, HR Low/HER2 Negative
    View official trial listing →
  • Recruiting NCT NCT06188520

    A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

    Not yet reported, Not yet reported AstraZeneca 564 participants Est. completion 2027-08-04 14 sites Stand-alone
    Other conditions: ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
    View official trial listing →
  • Recruiting NCT NCT06197581

    Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

    Not yet reported Cancer Institute and Hospital, Chinese Academy of Medical Sciences 148 participants Est. completion 2027-01-15 1 site
    Other conditions: Breast Cancer, Familial Male, Radiotherapy; Complications, Chemotherapeutic Toxicity, Immune Checkpoint Inhibitor, CDK4/6 Inhibitor, Trastuzumab, Pertuzumab, PARP Inhibitor
    View official trial listing →
  • Recruiting NCT NCT06207734

    Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

    Not yet reported Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 120 participants Est. completion 2028-07-10 13 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06307249

    Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA

    Not yet reported Lebanese University 50 participants Est. completion 2027-12 2 sites Stand-alone
    Other conditions: Cancer, Solid Tumor, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Targeted Therapy, Chemotherapy, Immunotherapy, Precision Therapy
    View official trial listing →
  • Recruiting NCT NCT06364956

    Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

    Not yet reported, Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 36 participants Est. completion 2026-06 8 sites Stand-alone
    Other conditions: Bladder Cancer
    View official trial listing →
  • Recruiting NCT NCT06377852

    The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

    Not yet reported American Society of Clinical Oncology 500 participants Est. completion 2028-09-01 73 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06380751

    Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

    Not yet reported AstraZeneca 788 participants Est. completion 2031-12-30 306 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06388122

    DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

    Mayo Clinic 100 participants Est. completion 2031-06-15 1 site
    Other conditions: HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Metastatic Breast Cancer, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06478927

    Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib

    Not yet reported Henan Cancer Hospital 22 participants Est. completion 2027-01-15 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06486883

    Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

    Not yet reported MedSIR 200 participants Est. completion 2028-01 79 sites
    Other conditions: Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06736704

    SNV4818 in Participants With Advanced Solid Tumors

    Not yet reported, Not yet reported Pikavation Therapeutics, Inc. 320 participants Est. completion 2027-06 12 sites Stand-alone
    Other conditions: Advanced Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT06739395

    Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

    Not yet reported Tianjin Medical University Second Hospital 300 participants Est. completion 2027-05-01 1 site Stand-alone
    Other conditions: Solid Tumor, Precision Medicine
    View official trial listing →
  • Recruiting NCT NCT06753747

    A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

    Not yet reported, Not yet reported West China Hospital 45 participants Est. completion 2028-09 1 site Stand-alone
    Other conditions: Esophagus Cancer
    View official trial listing →
  • Recruiting NCT NCT06757634

    Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

    Not yet reported Celcuity Inc 1180 participants Est. completion 2033-07-30 203 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06805812

    Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

    Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3500 participants Est. completion 2040-12-31 24 sites
    Other conditions: Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma, Breast Diseases, Breast Neoplasms, Breast Neoplasms, Male, Breast Cancer, Breast Cancer With Metastatic Bone Disease, Breast Cancers, Breast Neoplasm, Breast Tumors, HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer, HR+ Advanced or Metastatic Breast Cancer, HR+/HER2- Breast Cancer, HRpos Breast Neoplasms, HR-positive, HER2-negative Advanced Breast Cancer, HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer, HR-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Breast Neoplasms, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone Receptor Positive Metastatic Breast Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer, Hormone Receptor Negative Breast Cancer, Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer, Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Hormone Receptor (HR)-Positive Breast Cancer, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Palbociclib, Ribociclib, Abemaciclib, CDK4/6 Inhibitor, CDK4/6 Inhibitors
    View official trial listing →
  • Recruiting NCT NCT06843967

    A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 54 participants Est. completion 2028-08-19 7 sites Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Recruiting NCT NCT06856200

    A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

    Not yet reported Fudan University 36 participants Est. completion 2026-06 1 site Stand-alone
    Other conditions: Advanced HR - Positive, HER2 - Negative Breast Cancer, Resistant to (Neo)Adjuvant Endocrine Therapy
    View official trial listing →
  • Recruiting NCT NCT06895733

    Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

    Not yet reported, Not yet reported Tianjin Medical University Second Hospital 65 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Solid Tumor, Adult, Next-generation Sequencing, Precision Medicine
    View official trial listing →
  • Recruiting NCT NCT06940349

    Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors

    Not yet reported, Not yet reported Rabin Medical Center 100 participants Est. completion 2028-01-01 1 site Stand-alone
    Other conditions: Solid Tumors Refractory to Standard Therapy
    View official trial listing →
  • Recruiting NCT NCT06947811

    A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations

    Not yet reported, Not yet reported Sun Yat-sen University 71 participants Est. completion 2027-03 1 site Stand-alone
    Other conditions: EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
    View official trial listing →
  • Recruiting NCT NCT06959979

    Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma

    Not yet reported Fondazione Policlinico Universitario Agostino Gemelli IRCCS 60 participants Est. completion 2027-02-28 1 site Stand-alone
    Other conditions: Medulloblastoma, Childhood
    View official trial listing →
  • Recruiting NCT NCT06997029

    A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

    Not yet reported Bristol-Myers Squibb 234 participants Est. completion 2028-12-14 21 sites Stand-alone
    Other conditions: Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
    View official trial listing →
  • Recruiting NCT NCT07002177

    A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

    Not yet reported, Not yet reported Forward Pharmaceuticals Co., Ltd. 196 participants Est. completion 2028-11-01 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Locally Advanced Breast Cancer (LABC), ER+ Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07021911

    Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer

    Fondazione Policlinico Universitario Campus Bio-Medico 300 participants Est. completion 2029-05-17 1 site
    Other conditions: Breast Cancer, Radiotherapy; Complications
    View official trial listing →
  • Recruiting NCT NCT07037199

    Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer

    Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 45 participants Est. completion 2030-06-30 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07123090

    A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

    Not yet reported Stephanie Berg 25 participants Est. completion 2028-04-01 2 sites Stand-alone
    Other conditions: Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer, Translocation Renal Cell Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07174336

    A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

    Not yet reported Eli Lilly and Company 800 participants Est. completion 2033-05 360 sites Stand-alone
    Other conditions: Breast Neoplasms, Neoplasm Metastasis
    View official trial listing →
  • Recruiting NCT NCT07180160

    Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

    Not yet reported Wenjin Yin 123 participants Est. completion 2028-03 1 site Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07347600

    A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

    Hoffmann-La Roche 500 participants Est. completion 2029-12-31 30 sites
    Other conditions: Locally Advanced Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07407439

    Real-world Studies of CDK4/6 Inhibitors

    Tianjin Medical University Cancer Institute and Hospital 245 participants Est. completion 2027-06-01 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07491380

    Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)

    Not yet reported Institut Curie 90 participants Est. completion 2029-01-23 2 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07492641

    BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

    Not yet reported BeOne Medicines 1056 participants Est. completion 2037-08-07 162 sites
    Other conditions: HR+/HER2- Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07558733

    Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

    Not yet reported, Not yet reported Faeth Therapeutics 32 participants Est. completion 2033-05 7 sites
    Other conditions: HR+ HER2- Breast Cancer
    View official trial listing →
  • Completed NCT NCT00141297

    A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

    Not yet reported Pfizer 74 participants Est. completion 2014-12 4 sites
    Other conditions: Neoplasms, Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT00420056

    An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.

    Not yet reported Pfizer 17 participants Est. completion 2012-03 6 sites
    Other conditions: Lymphoma, Mantle-Cell
    View official trial listing →
  • Completed NCT NCT00555906

    An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

    Not yet reported Pfizer 53 participants Est. completion 2013-03 19 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00721409

    Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

    Not yet reported Pfizer 177 participants Est. completion 2017-12-20 104 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01037790

    Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer

    Not yet reported Abramson Cancer Center at Penn Medicine 304 participants Est. completion 2019-10 1 site
    Other conditions: Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Familial Testicular Germ Cell Tumor, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Male Breast Cancer, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Monodermal and Highly Specialized Teratoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Melanoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Rectal Cancer, Stage III Extragonadal Non-seminomatous Germ Cell Tumor, Stage III Extragonadal Seminoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Extragonadal Non-seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Melanoma, Stage IV Ovarian Germ Cell Tumor, Stage IV Rectal Cancer, Testicular Immature Teratoma, Testicular Mature Teratoma
    View official trial listing →
  • Terminated NCT NCT01111188

    Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

    Not yet reported Weill Medical College of Cornell University 20 participants Est. completion 2019-04-12 1 site
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01209598

    PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma

    Not yet reported Memorial Sloan Kettering Cancer Center 90 participants Est. completion 2016-10-25 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Sarcoma
    View official trial listing →
  • Terminated NCT NCT01227434

    A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma

    Not yet reported University of California, San Francisco 23 participants Est. completion 2013-12 1 site
    Obstructive sleep apnea Other conditions: Glioblastoma, Anaplastic Astrocytoma
    View official trial listing →
  • Completed NCT NCT01291017

    Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.

    Not yet reported University of Florida 19 participants Est. completion 2015-02 2 sites
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT01320592

    PD0332991/Paclitaxel in Advanced Breast Cancer

    Not yet reported Abramson Cancer Center at Penn Medicine 28 participants Est. completion 2019-05 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01356628

    A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 23 participants Est. completion 2023-12-16 1 site
    Other conditions: Advanced Hepatocellular Carcinoma, HCC, Liver Cancer
    View official trial listing →
  • Status unknown NCT NCT01522989

    PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies

    Not yet reported Georgetown University 37 participants Est. completion 2020-12 1 site
    Other conditions: Advanced Solid Tumor Malignancies
    View official trial listing →
  • Completed NCT NCT01536743

    A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

    Not yet reported Jonsson Comprehensive Cancer Center 26 participants Est. completion 2020-02-24 1 site
    Other conditions: Ovarian Epithelial Carcinoma
    View official trial listing →
  • Completed NCT NCT01602887

    Relative Bioavailability Study

    Not yet reported Pfizer 24 participants Est. completion 2012-11 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01684215

    A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer

    Not yet reported Pfizer 61 participants Est. completion 2018-10-25 16 sites
    Other conditions: Neoplasms, Breast Neoplasms
    View official trial listing →
  • Terminated NCT NCT01701375

    A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2 participants Est. completion 2013-04 2 sites
    Other conditions: Relapsed Acute Leukemia, Refractory Acute Leukemia, High-Risk Myelodysplasia
    View official trial listing →
  • Status unknown NCT NCT01709370

    Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women

    Not yet reported Organisation for Oncology and Translational Research 45 participants 1 site
    Other conditions: ER Positive, HER2 Negative Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT01723774

    PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

    Not yet reported Washington University School of Medicine 84 participants Est. completion 2026-08-24 4 sites
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT01740427

    A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

    Not yet reported Pfizer 666 participants Est. completion 2023-11-09 305 sites
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT01756768

    A Single-Radiolabeled Dose Mass Balance Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] Palbociclib (PD-0332991) In Healthy Male Volunteers

    Not yet reported Pfizer 6 participants Est. completion 2013-03 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01756781

    A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.

    Not yet reported Pfizer 26 participants Est. completion 2013-07 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01802476

    A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)

    Not yet reported Pfizer 14 participants Est. completion 2013-06 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01821066

    A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

    Not yet reported Pfizer 25 participants Est. completion 2013-08 1 site
    Other conditions: Healthy
    View official trial listing →
  • Terminated NCT NCT01823835

    A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

    Not yet reported, Not yet reported Genentech, Inc. 152 participants Est. completion 2020-03-13 14 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT01844323

    A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract

    Not yet reported Pfizer 24 participants Est. completion 2013-08 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01864746

    A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

    Not yet reported GBG Forschungs GmbH 1250 participants Est. completion 2020-12-21 11 sites Stand-alone
    Other conditions: Breast Cancer, Hormonreceptor Positive, Her2-normal, Postneoadjuvant Treatment With CDK 4/6 Inhibitor, CPS-EG Score
    View official trial listing →
  • Completed NCT NCT01904747

    Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption

    Not yet reported Pfizer 28 participants Est. completion 2013-10 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01906125

    A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market Product

    Not yet reported Pfizer 73 participants Est. completion 2014-01 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01907607

    Efficacy and Safety of PD-0332991 in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib

    Not yet reported Institut Bergonié 29 participants Est. completion 2019-02 9 sites
    Other conditions: Advanced Gastrointestinal Stromal Tumors
    View official trial listing →
  • Completed NCT NCT01918176

    Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)

    Not yet reported Pfizer 26 participants Est. completion 2013-12 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01942135

    Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

    Not yet reported Pfizer 521 participants Est. completion 2022-09-28 247 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT01953731

    A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)

    Not yet reported Pfizer 15 participants Est. completion 2014-01 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01976169

    Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)

    Not yet reported University of Texas Southwestern Medical Center 29 participants Est. completion 2021-05-19 1 site
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT02008734

    Randomized Phase II Study to Assess PD 0332991 in Breast Cancer

    Not yet reported Gustave Roussy, Cancer Campus, Grand Paris 132 participants Est. completion 2016-01 1 site
    Other conditions: Untreated Operable Early Breast Cancer
    View official trial listing →
  • Completed NCT NCT02022982

    PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

    Not yet reported Dana-Farber Cancer Institute 60 participants Est. completion 2021-06-30 1 site Stand-alone
    Other conditions: KRAS Mutant Non-Small Cell Lung Cancer, Solid Tumors
    View official trial listing →
  • Completed NCT NCT02028507

    Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors

    Not yet reported Spanish Breast Cancer Research Group 693 participants Est. completion 2021-01-11 37 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02030483

    Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma

    Not yet reported Weill Medical College of Cornell University 9 participants Est. completion 2016-07 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02040857

    Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

    Not yet reported Dana-Farber Cancer Institute 162 participants Est. completion 2024-12-27 10 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02041273

    Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions

    Not yet reported Pfizer 36 participants Est. completion 2014-03 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02059213

    A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

    Not yet reported University of Michigan Rogel Cancer Center 72 participants Est. completion 2019-06-04 8 sites Stand-alone
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT02059330

    A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects

    Not yet reported Pfizer 27 participants Est. completion 2014-06 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02065063

    A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

    Not yet reported GlaxoSmithKline 28 participants Est. completion 2016-06-23 3 sites Stand-alone
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT02083640

    Relative Bioavailability For Palbociclib Formulations

    Not yet reported Pfizer 30 participants Est. completion 2014-05 1 site
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02085538

    Study Of Palbociclib (PD-0332991) In Renal Impairment

    Not yet reported Pfizer 31 participants Est. completion 2016-05 3 sites Stand-alone
    Other conditions: Renal Impairment
    View official trial listing →
  • Completed NCT NCT02097329

    Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food

    Not yet reported Pfizer 27 participants Est. completion 2014-06 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT02101034

    PD 0332991 and Cetuximab in Patients With Incurable SCCHN

    Not yet reported, Not yet reported Washington University School of Medicine 96 participants Est. completion 2023-11-10 5 sites
    Other conditions: Carcinoma, Squamous Cell of Head and Neck
    View official trial listing →
  • Completed NCT NCT02131298

    Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib

    Not yet reported Pfizer 12 participants Est. completion 2014-06 1 site
    Other conditions: Healthy
    View official trial listing →
  • No Longer Available NCT NCT02142868

    Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

    Pfizer 55 sites
    Other conditions: Advanced Breast Cancer (Female)
    View official trial listing →
  • Completed NCT NCT02154490

    Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

    SWOG Cancer Research Network 1864 participants Est. completion 2022-04-15 1004 sites
    Other conditions: Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
    View official trial listing →
  • Active, not recruiting NCT NCT02159755

    Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

    Not yet reported National Cancer Institute (NCI) 28 participants Est. completion 2027-04-30 4 sites Stand-alone
    Other conditions: Recurrent Mantle Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT02202200

    Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma

    Not yet reported, Not yet reported Assistance Publique - Hôpitaux de Paris 40 participants Est. completion 2018-08 1 site
    Other conditions: Melanoma BRAF V600E/K Mutated, CDNKN2A Loss Defined
    View official trial listing →
  • Completed NCT NCT02222441

    Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)

    Not yet reported Pfizer 14 participants Est. completion 2014-12 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Terminated NCT NCT02255461

    Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

    Not yet reported Pediatric Brain Tumor Consortium 35 participants Est. completion 2019-02-25 11 sites Stand-alone
    Obstructive sleep apnea Other conditions: Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
    View official trial listing →
  • Completed NCT NCT02264613

    ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

    Not yet reported, Not yet reported Aileron Therapeutics, Inc. 142 participants Est. completion 2020-04 13 sites Stand-alone
    Other conditions: Solid Tumor, Lymphoma, Peripheral T-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02296801

    A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer

    Not yet reported NSABP Foundation Inc 307 participants Est. completion 2019-03 52 sites Stand-alone
    Other conditions: Breast Cancer, Breast Carcinoma, Breast Tumors
    View official trial listing →
  • Completed NCT NCT02297438

    A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

    Not yet reported Pfizer 340 participants Est. completion 2025-02-24 54 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Status unknown NCT NCT02310243

    Study of Palbociclib in MLL-rearranged Acute Leukemias

    Not yet reported, Not yet reported University of Ulm 50 participants Est. completion 2019-07 24 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT02311946

    A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

    Not yet reported Pfizer 60 participants Est. completion 2015-04 3 sites Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Terminated NCT NCT02334527

    Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy

    Not yet reported UNC Lineberger Comprehensive Cancer Center 12 participants Est. completion 2017-09-28 3 sites
    Other conditions: Metastatic Urothelial Carcinoma (UC)
    View official trial listing →
  • Completed NCT NCT02334800

    A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib

    Not yet reported Pfizer 28 participants Est. completion 2016-10-09 2 sites Stand-alone
    Other conditions: Healthy, Hepatic Insufficiency
    View official trial listing →
  • Terminated NCT NCT02349633

    Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

    Not yet reported, Not yet reported Pfizer 65 participants Est. completion 2020-05-28 15 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT02384239

    A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer

    Not yet reported University of California, San Francisco 70 participants Est. completion 2021-01-31 9 sites Stand-alone
    Other conditions: Metastatic Breast Cancer, Hormone Receptor Positive
    View official trial listing →
  • Completed NCT NCT02389842

    PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib

    Not yet reported Royal Marsden NHS Foundation Trust 79 participants Est. completion 2021-05-26 2 sites Stand-alone
    Other conditions: Advanced Solid Tumours, Breast Cancer
    View official trial listing →
  • Completed NCT NCT02400567

    Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women

    Not yet reported UNICANCER 125 participants Est. completion 2020-09 2 sites Stand-alone
    Other conditions: Neoadjuvant Operable Breast Cancer
    View official trial listing →
  • Completed NCT NCT02448420

    Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

    Not yet reported SOLTI Breast Cancer Research Group 73 participants Est. completion 2023-11-30 35 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT02448771

    A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 36 participants Est. completion 2021-03-03 2 sites Stand-alone
    Other conditions: Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02465060

    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    Not yet reported National Cancer Institute (NCI) 6452 participants Est. completion 2026-12-31 1410 sites Stand-alone
    Other conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
    View official trial listing →
  • Completed NCT NCT02491983

    Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer

    Not yet reported MedSIR 486 participants Est. completion 2020-01 48 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT02499120

    Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

    Not yet reported Pfizer 125 participants Est. completion 2022-09-07 71 sites Stand-alone
    Other conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    View official trial listing →
  • Completed NCT NCT02499146

    Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

    Not yet reported Pfizer 26 participants Est. completion 2024-12-24 7 sites Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT02501902

    Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

    Not yet reported Pfizer 76 participants Est. completion 2018-12-27 26 sites Stand-alone
    Other conditions: Metastatic Pancreatic Ductal Adenocarcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT02513394

    PALbociclib CoLlaborative Adjuvant Study

    Not yet reported Alliance Foundation Trials, LLC. 5796 participants Est. completion 2028-12 437 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02530320

    Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

    Not yet reported Grupo Español de Investigación en Neurooncología 34 participants Est. completion 2020-03 11 sites Stand-alone
    Other conditions: Oligodendroglioma, Oligoastrocytoma
    View official trial listing →
  • Completed NCT NCT02530424

    "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "

    Not yet reported Fondazione Michelangelo 102 participants Est. completion 2019-11 7 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT02536742

    Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer

    Not yet reported ETOP IBCSG Partners Foundation 124 participants Est. completion 2022-12-22 19 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT02549430

    To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy

    Not yet reported Fondazione Sandro Pitigliani 115 participants Est. completion 2017-02-09 6 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02592083

    Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors

    Not yet reported Thomas Hatschek 10 participants Est. completion 2029-02 1 site Stand-alone
    Other conditions: Early-Stage Breast Carcinoma, Hormone Receptor Positive Tumor
    View official trial listing →
  • Status unknown NCT NCT02592746

    A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC

    Not yet reported Samsung Medical Center 182 participants Est. completion 2021-06 2 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT02599714

    Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer

    Not yet reported AstraZeneca 54 participants Est. completion 2023-11-23 7 sites Stand-alone
    Other conditions: Advanced and Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT02600923

    Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate

    Not yet reported Pfizer 131 participants Est. completion 2019-05-28 24 sites Stand-alone
    Other conditions: Advanced Breast Cancer Female
    View official trial listing →
  • Active, not recruiting NCT NCT02603679

    Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases

    Not yet reported Thomas Hatschek 181 participants Est. completion 2031-12-31 3 sites Stand-alone
    Other conditions: Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor
    View official trial listing →
  • Active, not recruiting NCT NCT02605486

    Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 46 participants Est. completion 2026-11 5 sites Stand-alone
    Other conditions: Metastatic Breast Cancer (MBC)
    View official trial listing →
  • Active, not recruiting NCT NCT02624973

    PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial

    Not yet reported Haukeland University Hospital 200 participants Est. completion 2030-06 7 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02626507

    Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

    Not yet reported Hoffman Oncology 18 participants Est. completion 2022-03-15 2 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02630693

    Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

    Not yet reported Canadian Cancer Trials Group 180 participants Est. completion 2023-11-29 22 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02664935

    National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

    Not yet reported University of Birmingham 423 participants Est. completion 2023-11-29 25 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, Adenocarcinoma
    View official trial listing →
  • Completed NCT NCT02668666

    Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

    Not yet reported Oana Danciu, MD 49 participants Est. completion 2023-10-24 7 sites Stand-alone
    Other conditions: Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT02679755

    Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer

    Not yet reported Pfizer 252 participants Est. completion 2019-07-25 34 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02684032

    A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

    Not yet reported Celcuity Inc 141 participants Est. completion 2022-01-19 41 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02690480

    Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer

    Not yet reported Spanish Breast Cancer Research Group 189 participants Est. completion 2023-12 32 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT02692755

    Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer

    Not yet reported, Not yet reported Georgetown University 35 participants Est. completion 2021-03-23 6 sites Stand-alone
    Other conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT02730429

    Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer

    Not yet reported Nordic Society of Gynaecological Oncology - Clinical Trials Unit 78 participants Est. completion 2021-12-15 1 site Stand-alone
    Other conditions: Endometrial Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02738866

    Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 60 participants Est. completion 2026-12 5 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT02760030

    Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

    Not yet reported Ohio State University Comprehensive Cancer Center 14 participants Est. completion 2025-08-31 3 sites Stand-alone
    Other conditions: Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02764541

    Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

    Not yet reported Dana-Farber Cancer Institute 195 participants Est. completion 2031-04 11 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT02774681

    Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

    Not yet reported Northwestern University 12 participants Est. completion 2020-02-16 3 sites Stand-alone
    Other conditions: Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02778685

    Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

    Not yet reported City of Hope Medical Center 47 participants Est. completion 2026-03-30 7 sites Stand-alone
    Other conditions: Metastatic Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
    View official trial listing →
  • Completed NCT NCT02785939

    Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

    Not yet reported, Not yet reported SWOG Cancer Research Network 53 participants Est. completion 2019-06 1065 sites Stand-alone
    Other conditions: CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
    View official trial listing →
  • Completed NCT NCT02806050

    Palbociclib and FES PET

    Not yet reported University Medical Center Groningen 30 participants Est. completion 2022-09-28 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT02806648

    A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)

    Not yet reported Grupo Espanol de Tumores Neuroendocrinos 21 participants Est. completion 2018-01 9 sites Stand-alone
    Other conditions: Pancreatic Neuroendocrine Cancer
    View official trial listing →
  • Completed NCT NCT02866149

    Analysis of Circulating Tumor Markers in the Blood (ALCINA)

    Not yet reported Institut Curie 682 participants Est. completion 2024-09 5 sites
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT02871791

    Palbociclib With Everolimus + Exemestane In BC

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 41 participants Est. completion 2021-09 1 site Stand-alone
    Other conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer
    View official trial listing →
  • Completed NCT NCT02894398

    Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

    Not yet reported iOMEDICO AG 388 participants Est. completion 2023-02-15 70 sites Stand-alone
    Other conditions: Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
    View official trial listing →
  • Completed NCT NCT02897375

    Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

    Not yet reported Emory University 71 participants Est. completion 2021-10-15 1 site Stand-alone
    Other conditions: Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer, Sarcoma, Colorectal Cancer, Head and Neck Cancer, Cancer of Unknown Primary, Bladder Cancer, Ovarian Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02905318

    Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer

    Not yet reported Canadian Cancer Trials Group 19 participants Est. completion 2026-12-30 7 sites Stand-alone
    Other conditions: Prostate Cancer
    View official trial listing →
  • Terminated NCT NCT02907918

    Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer

    Not yet reported Washington University School of Medicine 26 participants Est. completion 2020-09-23 3 sites Stand-alone
    Other conditions: Breast Cancer, Cancer of Breast, Breast Carcinoma
    View official trial listing →
  • Completed NCT NCT02913430

    Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

    Not yet reported Shannon Puhalla 7 participants Est. completion 2024-04-30 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT02917005

    PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer

    Not yet reported Hamdy A. Azim 160 participants Est. completion 2023-12 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02942355

    Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer

    Not yet reported Wake Forest University Health Sciences 40 participants Est. completion 2028-06-30 1 site Stand-alone
    Other conditions: Female Breast Carcinoma, Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT02947685

    Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

    Not yet reported Alliance Foundation Trials, LLC. 518 participants Est. completion 2026-07-31 106 sites Stand-alone
    Other conditions: HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03006172

    To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

    Not yet reported Genentech, Inc. 200 participants Est. completion 2026-12-31 12 sites Stand-alone
    Other conditions: Breast Cancer, Solid Tumor
    View official trial listing →
  • Completed NCT NCT03007979

    Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

    Not yet reported Washington University School of Medicine 55 participants Est. completion 2023-03-31 2 sites Stand-alone
    Other conditions: Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
    View official trial listing →
  • Status unknown NCT NCT03024489

    Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma

    Not yet reported, Not yet reported Mahidol University 27 participants Est. completion 2024-12-31 1 site Stand-alone
    Other conditions: Head and Neck Cancer, Locally Advanced
    View official trial listing →
  • Completed NCT NCT03054363

    Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

    Not yet reported, Not yet reported University of Colorado, Denver 42 participants Est. completion 2023-02-07 6 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Suspended NCT NCT03065062

    Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

    Not yet reported Dana-Farber Cancer Institute 75 participants Est. completion 2027-01-31 3 sites Stand-alone
    Other conditions: Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer, Pancreatic Cancer
    View official trial listing →
  • Terminated NCT NCT03065387

    Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

    Not yet reported M.D. Anderson Cancer Center 84 participants Est. completion 2026-04-23 1 site Stand-alone
    Other conditions: Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation, ERBB2 Gene Amplification, ERBB2 Gene Mutation, ERBB3 Gene Mutation, ERBB4 Gene Mutation, KRAS Gene Mutation, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
    View official trial listing →
  • Completed NCT NCT03065621

    Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)

    Not yet reported Jules Bordet Institute 100 participants Est. completion 2023-02-01 5 sites Stand-alone
    Other conditions: Breast Cancer Female
    View official trial listing →
  • Completed NCT NCT03079011

    PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

    Not yet reported UNICANCER 1017 participants Est. completion 2025-09-22 82 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03088059

    Biomarker-based Study in R/M SCCHN

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 340 participants Est. completion 2025-12 36 sites Stand-alone
    Other conditions: Carcinoma, Squamous Cell of Head and Neck
    View official trial listing →
  • Completed NCT NCT03110744

    CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma

    Not yet reported University Hospital Heidelberg 43 participants Est. completion 2022-12-22 3 sites Stand-alone
    Other conditions: Chordoma
    View official trial listing →
  • Withdrawn NCT NCT03123744

    Histology-Independent Study of Palbociclib in Patients With Advanced Cancer

    Not yet reported Razelle Kurzrock, MD Est. completion 2024-02-01 1 site Stand-alone
    Other conditions: Cancer, Advanced
    View official trial listing →
  • Terminated NCT NCT03128619

    Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

    Not yet reported Jonsson Comprehensive Cancer Center 10 participants Est. completion 2022-03-31 1 site Stand-alone
    Other conditions: Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Postmenopausal, Progesterone Receptor Positive, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03132454

    Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

    Not yet reported M.D. Anderson Cancer Center 32 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03147287

    Palbociclib After CDK and Endocrine Therapy (PACE)

    Not yet reported Dana-Farber Cancer Institute 220 participants Est. completion 2026-12-30 22 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03155620

    Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

    Not yet reported National Cancer Institute (NCI) 1377 participants Est. completion 2027-01-06 172 sites Stand-alone
    Obstructive sleep apnea Other conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Rhabdoid Tumor, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Wilms Tumor
    View official trial listing →
  • Completed NCT NCT03158389

    NCT Neuro Master Match - N²M² (NOA-20)

    Not yet reported, Not yet reported University Hospital Heidelberg 228 participants Est. completion 2023-02-22 13 sites Stand-alone
    Other conditions: Glioblastoma, Adult
    View official trial listing →
  • Completed NCT NCT03159195

    Ibrance Real World Insights

    Pfizer 652 participants Est. completion 2021-06-24 1 site
    Other conditions: Malignant Neoplasm of Breast
    View official trial listing →
  • Completed NCT NCT03170206

    Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

    Not yet reported Dana-Farber Cancer Institute 34 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Lung Cancer
    View official trial listing →
  • Completed NCT NCT03184090

    Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC

    Not yet reported MedSIR 33 participants Est. completion 2020-10-27 15 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT03194373

    Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Not yet reported University of Michigan Rogel Cancer Center 21 participants Est. completion 2020-03-17 3 sites Stand-alone
    Other conditions: Squamous Cell Carcinoma of the Head and Neck
    View official trial listing →
  • Status unknown NCT NCT03219554

    A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor

    Not yet reported Samsung Medical Center 33 participants Est. completion 2020-12 1 site Stand-alone
    Other conditions: Thymic Cancer
    View official trial listing →
  • Terminated NCT NCT03220178

    Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy

    Not yet reported Palleos Healthcare GmbH 532 participants Est. completion 2021-12-07 1 site Stand-alone
    Other conditions: Breast Neoplasm
    View official trial listing →
  • Completed NCT NCT03220191

    Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib

    Not yet reported Pfizer 12 participants Est. completion 2017-09-26 1 site Stand-alone
    Other conditions: Healthy Volunteer
    View official trial listing →
  • Completed NCT NCT03227328

    CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

    Not yet reported Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 52 participants Est. completion 2022-07-01 20 sites
    Other conditions: Hormone Receptor Positive Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT03238196

    Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer

    Not yet reported Vanderbilt-Ingram Cancer Center 35 participants Est. completion 2024-03-20 6 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03239015

    Efficacy and Safety of Precision Therapy in Refractory Tumor

    Not yet reported Baodong Qin 300 participants Est. completion 2023-12-31 1 site Stand-alone
    Other conditions: Rare Tumor, Refractory Tumor
    View official trial listing →
  • Status unknown NCT NCT03242382

    Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.

    Not yet reported Grupo Espanol de Investigacion en Sarcomas 40 participants Est. completion 2024-09-30 19 sites Stand-alone
    Obstructive sleep apnea Other conditions: Soft-tissue Sarcoma, Chordoma
    View official trial listing →
  • Completed NCT NCT03280303

    Palbociclib in Real World Practice

    Pfizer 1285 participants Est. completion 2022-12-22 305 sites
    Other conditions: Advanced Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03281902

    Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy

    Mayo Clinic 68 participants Est. completion 2028-03-04 3 sites
    Other conditions: Advanced Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
    View official trial listing →
  • Terminated NCT NCT03284723

    PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

    Not yet reported Pfizer 95 participants Est. completion 2021-08-31 46 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Terminated NCT NCT03284957

    Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

    Not yet reported, Not yet reported Sanofi 136 participants Est. completion 2024-11-08 25 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03285568

    Patterns of Prescribing and Monitoring of Palbociclib

    Rush University Medical Center 67 participants Est. completion 2016-12-30
    Other conditions: Metastatic Breast Cancer, Advanced Breast Cancer, Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
    View official trial listing →
  • Active, not recruiting NCT NCT03304080

    Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

    Not yet reported, Not yet reported Icahn School of Medicine at Mount Sinai 44 participants Est. completion 2027-12-31 5 sites Stand-alone
    Other conditions: Breast Neoplasms, Breast Diseases
    View official trial listing →
  • Terminated NCT NCT03322215

    HR+/HER2- Advanced Breast Cancer and Endocrine Resistance

    Not yet reported Theodoros Foukakis 42 participants Est. completion 2023-10-31 9 sites Stand-alone
    Other conditions: Breast Cancer Metastatic
    View official trial listing →
  • Active, not recruiting NCT NCT03332797

    A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

    Not yet reported Genentech, Inc. 181 participants Est. completion 2027-07-31 23 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03355157

    A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).

    Not yet reported GBG Forschungs GmbH 130 participants Est. completion 2024-08-30 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT03377101

    Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

    Not yet reported National Cancer Institute (NCI) Est. completion 2018-08-07 Stand-alone
    Other conditions: Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Stage IV Breast Cancer AJCC v6 and v7
    View official trial listing →
  • Terminated NCT NCT03386929

    Survival Prolongation by Rationale Innovative Genomics

    Not yet reported, Not yet reported Worldwide Innovative Network Association 15 participants Est. completion 2022-12-29 5 sites Stand-alone
    Other conditions: Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB
    View official trial listing →
  • Active, not recruiting NCT NCT03389477

    Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

    Not yet reported Washington University School of Medicine 26 participants Est. completion 2027-04-06 1 site Stand-alone
    Other conditions: Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Status unknown NCT NCT03401359

    The Resistance and Immune Response to Palbociclib in Breast Cancer

    Not yet reported Samsung Medical Center 100 participants Est. completion 2022-10-31 1 site
    Other conditions: Breast Cancer Stage IV
    View official trial listing →
  • Status unknown NCT NCT03423199

    PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

    Not yet reported National Cancer Center, Japan 180 participants Est. completion 2025-09 23 sites Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT03425838

    Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

    Not yet reported Borstkanker Onderzoek Groep 1050 participants Est. completion 2028-12 72 sites
    Other conditions: Breast Neoplasm Female
    View official trial listing →
  • Active, not recruiting NCT NCT03439735

    Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 45 participants Est. completion 2027-11-01 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03445637

    Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®

    Pfizer 552 participants Est. completion 2025-07-13 1 site
    Other conditions: Breast Neoplasm
    View official trial listing →
  • Completed NCT NCT03446157

    Palbociclib and Cetuximab in Metastatic Colorectal Cancer

    Not yet reported UNC Lineberger Comprehensive Cancer Center 24 participants Est. completion 2026-01-26 1 site Stand-alone
    Other conditions: Cancer of the Colon, Colon Cancer, Colon Neoplasms, Colonic Cancer, Neoplasms, Colonic
    View official trial listing →
  • Completed NCT NCT03447132

    Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

    Not yet reported International Cancer Research Group, United Arab Emirates 354 participants Est. completion 2021-07-20 14 sites
    Other conditions: Breast Neoplasm Female
    View official trial listing →
  • Status unknown NCT NCT03454919

    Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations

    Not yet reported Peking University Cancer Hospital & Institute 60 participants Est. completion 2020-06-30
    Other conditions: Melanoma
    View official trial listing →
  • Completed NCT NCT03455270

    G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

    Not yet reported G1 Therapeutics, Inc. 107 participants Est. completion 2022-09-29 15 sites Stand-alone
    Other conditions: Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Neoplasm, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer
    View official trial listing →
  • Completed NCT NCT03471663

    A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

    Not yet reported InventisBio Co., Ltd 200 participants Est. completion 2023-10-18 15 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03472573

    Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 7 participants Est. completion 2022-06-09 1 site Stand-alone
    Other conditions: Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03478514

    Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

    Not yet reported Alliance Foundation Trials, LLC. 39 participants Est. completion 2026-08-30 9 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma, B Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03498378

    Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Not yet reported Kathryn Gold 24 participants Est. completion 2025-12-30 1 site Stand-alone
    Other conditions: Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Terminated NCT NCT03515200

    Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

    Not yet reported St. Jude Children's Research Hospital 12 participants Est. completion 2020-07-29 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
    View official trial listing →
  • Completed NCT NCT03526250

    Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

    Not yet reported National Cancer Institute (NCI) 23 participants Est. completion 2024-09-30 117 sites Stand-alone
    Obstructive sleep apnea Other conditions: Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Soft Tissue Sarcoma
    View official trial listing →
  • Completed NCT NCT03530696

    T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

    Not yet reported University of Arizona 55 participants Est. completion 2022-12-22 16 sites Stand-alone
    Other conditions: HER2-positive Breast Cancer, Breast Cancer, Breast Cancer Stage, Recurrent Breast Cancer, Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT03531645

    Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

    Not yet reported M.D. Anderson Cancer Center 18 participants Est. completion 2027-09-30 1 site
    Other conditions: Malignant Neoplasms of Female Genital Organs
    View official trial listing →
  • Terminated NCT NCT03535506

    Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery

    Not yet reported Georgetown University 17 participants Est. completion 2023-12-06 2 sites Stand-alone
    Other conditions: DCIS
    View official trial listing →
  • Completed NCT NCT03560531

    A Study of ZN-c5 in Subjects With Breast Cancer

    Not yet reported, Not yet reported Zeno Alpha Inc. 181 participants Est. completion 2022-12-22 38 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT03560856

    A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer

    Not yet reported Assistance Publique - Hôpitaux de Paris 54 participants Est. completion 2022-06-01
    Other conditions: Breast Cancer, HR+/HER2-negative Breast Cancer, Metastasis
    View official trial listing →
  • Active, not recruiting NCT NCT03573648

    Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 33 participants Est. completion 2026-12-30 4 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03609047

    Adjuvant Palbociclib in Elderly Patients With Breast Cancer

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 366 participants Est. completion 2026-09-30 73 sites Stand-alone
    Other conditions: Breast Cancer Stage II, Breast Cancer Stage III
    View official trial listing →
  • Active, not recruiting NCT NCT03616587

    Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

    Not yet reported AstraZeneca 396 participants Est. completion 2027-06-24 17 sites Stand-alone
    Other conditions: ER+ HER2- Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT03628066

    Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

    Not yet reported NSABP Foundation Inc 24 participants Est. completion 2021-01-30 15 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03633331

    Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

    Not yet reported Alliance for Clinical Trials in Oncology 93 participants Est. completion 2026-02-27 447 sites Stand-alone
    Other conditions: Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
    View official trial listing →
  • Completed NCT NCT03644186

    To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

    Not yet reported ETOP IBCSG Partners Foundation 147 participants Est. completion 2023-04-14 54 sites Stand-alone
    Other conditions: Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer
    View official trial listing →
  • Completed NCT NCT03685331

    HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

    Not yet reported Abramson Cancer Center at Penn Medicine 9 participants Est. completion 2025-12-01 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
    View official trial listing →
  • Completed NCT NCT03691493

    Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

    Not yet reported Emory University 36 participants Est. completion 2022-10-13 10 sites Stand-alone
    Other conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
    View official trial listing →
  • Terminated NCT NCT03709082

    Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

    Not yet reported, Not yet reported University of Kansas Medical Center 3 participants Est. completion 2021-02-03 5 sites Stand-alone
    Other conditions: HER2-positive Breast Cancer, Breast Cancer Metastatic
    View official trial listing →
  • Active, not recruiting NCT NCT03709680

    Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

    Not yet reported Pfizer 128 participants Est. completion 2025-10-18 101 sites Stand-alone
    Obstructive sleep apnea Other conditions: Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma
    View official trial listing →
  • Status unknown NCT NCT03756090

    The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer

    Not yet reported Zhejiang Cancer Hospital 100 participants Est. completion 2020-11-30 Stand-alone
    Other conditions: Breast Cancer, Breast Diseases, Breast Neoplasms
    View official trial listing →
  • Completed NCT NCT03774472

    Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 15 participants Est. completion 2024-04-17 1 site Stand-alone
    Other conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
    View official trial listing →
  • Completed NCT NCT03784014

    Molecular Profiling of Advanced Soft-tissue Sarcomas

    Not yet reported Institut National de la Santé Et de la Recherche Médicale, France 603 participants Est. completion 2026-01-20 17 sites Stand-alone
    Other conditions: Soft Tissue Sarcoma
    View official trial listing →
  • Completed NCT NCT03792256

    Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

    Not yet reported Children's Oncology Group 12 participants Est. completion 2023-09-30 19 sites Stand-alone
    Other conditions: Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma, T-cell Leukemia, Recurrent Disease, Acute Leukemia
    View official trial listing →
  • Completed NCT NCT03809988

    PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)

    Not yet reported MedSIR 198 participants Est. completion 2022-11-30 53 sites Stand-alone
    Other conditions: Breast Cancer, Advanced Breast Cancer, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
    View official trial listing →
  • Completed NCT NCT03819010

    Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -

    Not yet reported MedSIR 66 participants Est. completion 2019-12-31 18 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03820830

    Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

    Not yet reported ETOP IBCSG Partners Foundation 405 participants Est. completion 2029-01-01 53 sites Stand-alone
    Other conditions: Breast Cancer Recurrent
    View official trial listing →
  • Completed NCT NCT03844997

    Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia

    Not yet reported, Not yet reported Sudipto Mukherjee, MD, PhD, MPH 35 participants Est. completion 2024-01-24 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, AML
    View official trial listing →
  • Completed NCT NCT03854903

    WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

    Not yet reported Georgetown University 19 participants Est. completion 2025-01-09 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03870919

    Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

    Not yet reported UNICANCER 200 participants Est. completion 2027-10-23 26 sites
    Other conditions: Breast Cancer Stage IV, Radiotherapy, Surgery
    View official trial listing →
  • Terminated NCT NCT03878524

    Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

    Not yet reported OHSU Knight Cancer Institute 2 participants Est. completion 2020-12-10 1 site Stand-alone
    Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT03900884

    Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

    Not yet reported Peter MacCallum Cancer Centre, Australia 17 participants Est. completion 2025-12 3 sites Stand-alone
    Other conditions: Breast Neoplasm Female
    View official trial listing →
  • Completed NCT NCT03921866

    UK Ibrance Patient Program (IPP) Study

    Pfizer 191 participants Est. completion 2021-03-04 8 sites
    Other conditions: HR+/HER2- Locally Advanced, Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT03936270

    Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

    Not yet reported Latin American Cooperative Oncology Group 43 participants Est. completion 2023-05-02 5 sites Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03959891

    AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

    Not yet reported Massachusetts General Hospital 77 participants Est. completion 2027-08 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT03965845

    A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

    Not yet reported, Not yet reported Calithera Biosciences, Inc 53 participants Est. completion 2021-09-24 10 sites Stand-alone
    Other conditions: Solid Tumors, NSCLC, CRC, KRAS Gene Mutation
    View official trial listing →
  • Completed NCT NCT03969121

    Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

    Not yet reported Kyoto Breast Cancer Research Network 141 participants Est. completion 2021-12-23 25 sites
    Other conditions: Breast Cancer Female, Hormone Receptor Positive Malignant Neoplasm of Breast
    View official trial listing →
  • Completed NCT NCT03981614

    Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

    Not yet reported Academic and Community Cancer Research United 102 participants Est. completion 2024-07-02 7 sites Stand-alone
    Other conditions: Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Carcinoma
    View official trial listing →
  • Status unknown NCT NCT04047758

    Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

    Not yet reported Shengjing Hospital 420 participants Est. completion 2022-09-30 3 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04060862

    A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

    Not yet reported Hoffmann-La Roche 20 participants Est. completion 2023-08-29 20 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04072952

    A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

    Not yet reported, Not yet reported Arvinas Estrogen Receptor, Inc. 217 participants Est. completion 2026-03-05 16 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04075604

    A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer

    Not yet reported Bristol-Myers Squibb 23 participants Est. completion 2021-07-27 36 sites Stand-alone
    Other conditions: Breast Cancer, Cancer
    View official trial listing →
  • Completed NCT NCT04109261

    Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use Programe

    Fernando Moreno Antón 237 participants Est. completion 2019-09-01 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04129151

    Palbociclib + Ganitumab In Ewing Sarcoma

    Not yet reported Dana-Farber Cancer Institute 10 participants Est. completion 2022-12-15 3 sites Stand-alone
    Other conditions: Ewing Sarcoma, Ewing's Sarcoma Recurrent
    View official trial listing →
  • Completed NCT NCT04130152

    Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy

    Not yet reported SOLTI Breast Cancer Research Group 22 participants Est. completion 2022-02-24 8 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04137640

    Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy

    Not yet reported Shengjing Hospital 152 participants Est. completion 2026-05-31 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04176354

    Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

    Pfizer 813 participants Est. completion 2019-09-27 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04185883

    Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

    Not yet reported Amgen 610 participants Est. completion 2027-12-05 90 sites Stand-alone
    Other conditions: Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
    View official trial listing →
  • Active, not recruiting NCT NCT04191499

    A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

    Not yet reported, Not yet reported Hoffmann-La Roche 325 participants Est. completion 2027-11-15 135 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04216576

    A Study of the Use of Text Message Reminders to Take Palbociclib

    Not yet reported Memorial Sloan Kettering Cancer Center 45 participants Est. completion 2026-12-27 7 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT04220476

    CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer

    Not yet reported Weill Medical College of Cornell University Est. completion 2028-12-31
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04224272

    A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

    Not yet reported Jazz Pharmaceuticals 51 participants Est. completion 2025-06-30 13 sites Stand-alone
    Other conditions: HER2+/HR+ Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04247633

    High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

    Not yet reported Samsung Medical Center 578 participants Est. completion 2025-02 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04256941

    Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

    Not yet reported M.D. Anderson Cancer Center 4 participants Est. completion 2023-09-22 1 site Stand-alone
    Other conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT04288089

    A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

    Not yet reported Eisai Inc. 31 participants Est. completion 2027-03-31 8 sites Stand-alone
    Other conditions: Receptors, Estrogen, Genes, Erbb-2, Breast Neoplasms
    View official trial listing →
  • Status unknown NCT NCT04289974

    Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

    Chinese Academy of Medical Sciences 100 participants Est. completion 2022-04 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04318223

    Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

    Not yet reported Consorzio Oncotech 168 participants Est. completion 2023-07-31 19 sites Stand-alone
    Other conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04334330

    Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

    Not yet reported Sun Yat-sen University 34 participants Est. completion 2024-12-31 2 sites Stand-alone
    Other conditions: Breast Cancer, Brain Metastases
    View official trial listing →
  • Active, not recruiting NCT NCT04360941

    PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

    Not yet reported Royal Marsden NHS Foundation Trust 45 participants Est. completion 2027-07-31 9 sites Stand-alone
    Other conditions: Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer
    View official trial listing →
  • Completed NCT NCT04394247

    Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy

    Pfizer 242 participants Est. completion 2020-12-31 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04436744

    A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)

    Not yet reported Hoffmann-La Roche 221 participants Est. completion 2021-11-24 65 sites Stand-alone
    Other conditions: Early Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04438824

    Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

    Not yet reported Memorial Sloan Kettering Cancer Center 42 participants Est. completion 2027-06 7 sites Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Active, not recruiting NCT NCT04439201

    Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

    Not yet reported National Cancer Institute (NCI) 40 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
    View official trial listing →
  • Completed NCT NCT04460898

    RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

    Pfizer 195 participants Est. completion 2019-06-24 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04460911

    Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

    Pfizer 317 participants Est. completion 2022-04-01 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04478266

    Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

    Not yet reported Sanofi 1068 participants Est. completion 2023-05-26 249 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04483505

    Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.

    Not yet reported Fundacion CRIS de Investigación para Vencer el Cáncer 9 participants Est. completion 2023-04-04 8 sites Stand-alone
    Other conditions: Breast Cancer Metastatic, Hormone Receptor Positive Malignant Neoplasm of Breast
    View official trial listing →
  • Completed NCT NCT04494958

    Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer

    Not yet reported, Not yet reported Fundacion Oncosur 24 participants Est. completion 2023-12-14 8 sites Stand-alone
    Other conditions: Triple Negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT04498481

    TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

    Pfizer 1 participants Est. completion 2018-07-01 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT04498520

    Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

    Not yet reported Pamela Munster Est. completion 2025-06-30 Stand-alone
    Other conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Endometrioid Adenocarcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Breast Carcinoma, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
    View official trial listing →
  • Completed NCT NCT04517318

    Treatment After Palbociclib-containing Regimens

    Fudan University 200 participants Est. completion 2021-07-15 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04524728

    Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

    Istituti Clinici Scientifici Maugeri SpA 191 participants Est. completion 2020-06 1 site
    Other conditions: Breast, Neoplasm Malignant, Female
    View official trial listing →
  • Status unknown NCT NCT04526028

    Palbociclib in Combination With Fulvestrant Versus Fulvestrant in Advanced Breast Cancer: A Real-world Study in China

    Tianjin Medical University Cancer Institute and Hospital 612 participants Est. completion 2023-05-31 1 site
    Other conditions: Breast Cancer, Fulvestrant, Palbociclib
    View official trial listing →
  • Active, not recruiting NCT NCT04546009

    A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

    Not yet reported Hoffmann-La Roche 992 participants Est. completion 2027-07-31 255 sites Stand-alone
    Other conditions: Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04553133

    PF-07104091 as a Single Agent and in Combination Therapy

    Not yet reported Pfizer 157 participants Est. completion 2026-12-31 22 sites Stand-alone
    Other conditions: Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04567420

    DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

    Not yet reported Criterium, Inc. 70 participants Est. completion 2028-12-31 19 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT04585724

    Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

    Not yet reported Emory University Est. completion 2021-09-13 Stand-alone
    Other conditions: Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
    View official trial listing →
  • Status unknown NCT NCT04591431

    The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

    Not yet reported Fondazione per la Medicina Personalizzata 400 participants Est. completion 2025-06 37 sites Stand-alone
    Other conditions: Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT04605562

    Umbrella Biomarker-Guided Therapy in NPC

    Not yet reported Sun Yat-sen University 206 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Nasopharyngeal Carcinoma
    View official trial listing →
  • Status unknown NCT NCT04644432

    Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma

    Not yet reported Herlev and Gentofte Hospital 30 participants Est. completion 2022-09-06 1 site Stand-alone
    Other conditions: Metastatic Renal Cell Carcinoma, Kidney Neoplasm, Urologic Neoplasms, Urogenital Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT04653740

    Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer

    Not yet reported Centre Oscar Lambret 25 participants Est. completion 2026-06 1 site
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04669587

    ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

    Not yet reported, Not yet reported EnhancedBio USA Inc. 106 participants Est. completion 2024-01-31 8 sites Stand-alone
    Other conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT04671615

    A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

    Pfizer 559 participants Est. completion 2022-11-30 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT04708860

    Feasibility of Fasting & Exercise in Pts With HR+ MBC

    Not yet reported Dana-Farber Cancer Institute 30 participants Est. completion 2024-07-31 1 site Stand-alone
    Other conditions: Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04711252

    A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

    Not yet reported AstraZeneca 1370 participants Est. completion 2029-02-01 263 sites Stand-alone
    Other conditions: ER-Positive HER2-Negative Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04720768

    Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE

    Not yet reported, Not yet reported Peter MacCallum Cancer Centre, Australia 78 participants Est. completion 2024-12-04 4 sites Stand-alone
    Other conditions: Melanoma, Metastasis
    View official trial listing →
  • Completed NCT NCT04735367

    Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

    Pfizer 42 participants Est. completion 2023-09-29 13 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04736576

    Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy

    Not yet reported Pfizer 99 participants Est. completion 2023-03-24 20 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04767594

    First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

    Pfizer 1407 participants Est. completion 2028-04-30 192 sites
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Terminated NCT NCT04778982

    Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

    Jiangsu Alphamab Biopharmaceuticals Co., Ltd 4 participants Est. completion 2023-03-15 1 site
    Other conditions: HER2-positive Metastatic Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04801966

    Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

    Not yet reported Peter MacCallum Cancer Centre, Australia 3 participants Est. completion 2022-12-30 1 site Stand-alone
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT04818632

    AZD9833 China PK Study

    Not yet reported AstraZeneca 28 participants Est. completion 2023-09-07 4 sites Stand-alone
    Other conditions: ER+, HER2-, Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04852081

    Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

    Blokhin's Russian Cancer Research Center 1000 participants Est. completion 2021-12-01 1 site
    Other conditions: Breast Cancer Stage IV
    View official trial listing →
  • Status unknown NCT NCT04856371

    Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer

    Not yet reported Haihe Biopharma Co., Ltd. 228 participants Est. completion 2022-12 Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04858516

    Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer

    Not yet reported Guangdong Provincial People's Hospital 57 participants Est. completion 2025-04-30 Stand-alone
    Other conditions: Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT04858997

    Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients

    Not yet reported Zhejiang Cancer Hospital 150 participants Est. completion 2023-06-30 1 site Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT04862663

    Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

    Not yet reported AstraZeneca 893 participants Est. completion 2029-08-14 225 sites Stand-alone
    Other conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT04870034

    Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

    Not yet reported Roswell Park Cancer Institute Est. completion 2026-09-30 1 site Stand-alone
    Other conditions: Colorectal Carcinoma, Lung Adenocarcinoma, Malignant Solid Neoplasm, Pancreatic Carcinoma
    View official trial listing →
  • Withdrawn NCT NCT04872608

    A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center Est. completion 2023-04-25 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer, Unresectable Breast Cancer
    View official trial listing →
  • Completed NCT NCT04874025

    Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer

    Hospital San Carlos, Madrid 815 participants Est. completion 2022-06-08 36 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT04916509

    Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

    Pfizer 258 participants Est. completion 2022-12-27 7 sites
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT04920708

    Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

    Not yet reported Royal Marsden NHS Foundation Trust 57 participants Est. completion 2027-06 13 sites Stand-alone
    Other conditions: Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04931342

    A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

    Not yet reported Hoffmann-La Roche 176 participants Est. completion 2028-05-30 41 sites Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Completed NCT NCT04937660

    Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC

    Pfizer 185 participants Est. completion 2025-04-29 12 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Suspended NCT NCT04946864

    A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

    Not yet reported, Not yet reported Ascentage Pharma Group Inc. 65 participants Est. completion 2024-10-01 7 sites Stand-alone
    Other conditions: Breast Cancer, Solid Tumor, Adult
    View official trial listing →
  • Active, not recruiting NCT NCT04964934

    Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

    Not yet reported AstraZeneca 315 participants Est. completion 2028-09-01 264 sites Stand-alone
    Other conditions: ER-Positive HER2-Negative Breast Cancer
    View official trial listing →
  • Completed NCT NCT04992156

    Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET

    Fudan University 50 participants Est. completion 2022-04-15 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT04996160

    Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia

    Not yet reported Tanja Andrea Gruber 2 participants Est. completion 2023-10-16 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
    View official trial listing →
  • Status unknown NCT NCT05000736

    Comparative Effectiveness of Palbociclib Plus AI Versus Fulvestrant for HR+/HER2- ABC

    Chinese Academy of Medical Sciences 600 participants Est. completion 2022-09-01 1 site
    Other conditions: Hormone Receptor Positive Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT05012644

    Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone

    Pfizer 197 participants Est. completion 2021-12-09 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT05039177

    A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

    Not yet reported, Not yet reported Erasca, Inc. 101 participants Est. completion 2026-01-26 14 sites Stand-alone
    Other conditions: Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
    View official trial listing →
  • Completed NCT NCT05043506

    European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies

    Pfizer 1939 participants Est. completion 2023-11-02 64 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05051956

    Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?

    Namik Kemal University 140 participants Est. completion 2021-12-15 1 site
    Other conditions: Can the Geriatric Questionnaires Predict Adverse Effects in Geriatric Breast Cancer Patients Treated With Cyclin-dependent Kinase 4 and 6 Inhibitors
    View official trial listing →
  • Completed NCT NCT05063058

    Biomarker-driven Therapy for Melanoma

    Not yet reported Charite University, Berlin, Germany 100 participants Est. completion 2021-08 Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Terminated NCT NCT05065411

    Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

    Not yet reported Veru Inc. 5 participants Est. completion 2024-01-09 30 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT05067530

    Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study

    Not yet reported Medical University of Gdansk 126 participants Est. completion 2026-12-06 6 sites Stand-alone
    Other conditions: Triple Negative Breast Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT05069038

    Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

    Not yet reported University of Nebraska 51 participants Est. completion 2032-09 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05076695

    Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer

    Not yet reported Fudan University 37 participants Est. completion 2024-10-15 1 site Stand-alone
    Other conditions: Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer
    View official trial listing →
  • Completed NCT NCT05132101

    Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

    Pfizer 2758 participants Est. completion 2022-03-14 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05135104

    Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period

    Asociatia Oncohelp - Centrul de Oncologie Oncohelp 650 participants Est. completion 2024-05-25 7 sites
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT05141240

    A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

    Novartis Pharmaceuticals 4650 participants Est. completion 2020-06-15 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT05153135

    Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

    Novartis Pharmaceuticals 4320 participants Est. completion 2020-07-31 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT05153187

    Real-world Treatment Patterns of Endocrine Based Therapy Among Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor-2-negative (HR+/HER2-) Advanced Breast Cancer: An Analysis of Administrative Claims Data in Japan

    Pfizer 1170 participants Est. completion 2021-06-30 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT05155566

    Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

    Pfizer 847 participants Est. completion 2021-03-12 2 sites
    Other conditions: Breast Cancer Metastatic
    View official trial listing →
  • Withdrawn NCT NCT05176288

    Avelumab, Palbociclib and Axitinib in Advanced RCC

    Not yet reported Bradley A. McGregor, MD Est. completion 2027-08-31 Stand-alone
    Other conditions: Advanced Clear Cell Renal Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT05178888

    Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

    Not yet reported Mirati Therapeutics Inc. 11 participants Est. completion 2024-12-30 4 sites Stand-alone
    Other conditions: Advanced Solid Tumor
    View official trial listing →
  • Terminated NCT NCT05207709

    Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

    Not yet reported SOLTI Breast Cancer Research Group 61 participants Est. completion 2026-03-26 71 sites Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05226871

    Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

    Not yet reported Pfizer 35 participants Est. completion 2029-12-31 23 sites Stand-alone
    Other conditions: Breast Cancer, Head and Neck Cancer
    View official trial listing →
  • Withdrawn NCT NCT05238831

    SMMART Adaptive Clinical Treatment (ACT) Trial

    Not yet reported OHSU Knight Cancer Institute Est. completion 2026-05-31 Stand-alone
    Other conditions: Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT05238922

    Study of INCB123667 in Subjects With Advanced Solid Tumors

    Not yet reported Incyte Corporation 291 participants Est. completion 2027-08-31 41 sites Stand-alone
    Other conditions: Solid Tumors
    View official trial listing →
  • Withdrawn NCT NCT05244434

    Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer

    Not yet reported City of Hope Medical Center Est. completion 2023-01-26 Stand-alone
    Other conditions: Advanced Breast Adenocarcinoma, Advanced HER2-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor-Positive Breast Carcinoma, Metastatic Breast Adenocarcinoma, Metastatic HER2-Negative Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT05266105

    A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

    Not yet reported Olema Pharmaceuticals, Inc. 60 participants Est. completion 2026-03 8 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05277935

    Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib

    Not yet reported Beneficência Portuguesa de São Paulo 68 participants Est. completion 2025-03-01 4 sites
    Other conditions: Breast Neoplasm Female, Quality of Life
    View official trial listing →
  • Active, not recruiting NCT NCT05293964

    Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

    Not yet reported Jiangsu Simcere Pharmaceutical Co., Ltd. 214 participants Est. completion 2025-09-08 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05343117

    Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC

    Chinese Academy of Medical Sciences 400 participants Est. completion 2024-06-01 9 sites
    Other conditions: Hormone Receptor Positive Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT05361655

    Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

    Pfizer 2888 participants Est. completion 2021-09-01 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT05371275

    Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent Thromboinflammation

    Not yet reported biotx.ai GmbH Est. completion 2022-12 1 site Stand-alone
    Other conditions: COVID-19
    View official trial listing →
  • Terminated NCT NCT05384119

    Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

    Not yet reported Tvardi Therapeutics, Incorporated 6 participants Est. completion 2024-04-25 6 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT05399329

    Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

    Pfizer 693 participants Est. completion 2025-06-27 20 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05429684

    Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

    Not yet reported First Affiliated Hospital Xi'an Jiaotong University 120 participants Est. completion 2024-02-28 2 sites Stand-alone
    Other conditions: HER2+ Breast Cancer
    View official trial listing →
  • Completed NCT NCT05452798

    A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark

    Pfizer 1054 participants Est. completion 2022-08-01 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05464173

    Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With Palbociclib

    Not yet reported, Not yet reported Biyun Wang, MD 44 participants Est. completion 2025-05-01 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT05468697

    A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

    Not yet reported, Not yet reported Merck Sharp & Dohme LLC 60 participants Est. completion 2026-10-22 13 sites Stand-alone
    Other conditions: Renal Cell Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05501886

    Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

    Not yet reported Celcuity Inc 701 participants Est. completion 2026-12-31 235 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT05505175

    Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC

    Pfizer 121 participants Est. completion 2023-05-02 14 sites
    Other conditions: Breast Cancer, Breast Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05554367

    Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

    Not yet reported National Cancer Institute (NCI) 199 participants Est. completion 2028-08-26 265 sites Stand-alone
    Other conditions: Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT05563220

    Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

    Not yet reported, Not yet reported Stemline Therapeutics, Inc. 435 participants Est. completion 2028-12-28 83 sites Stand-alone
    Other conditions: Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT05584644

    A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer

    Pfizer 150 participants Est. completion 2022-02-22 6 sites
    Other conditions: Breast Cancer, Breast Carcinoma, Breast Neoplasms, Breast Tumors, Cancer of Breast
    View official trial listing →
  • Withdrawn NCT NCT05655598

    TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

    Not yet reported Brown University Est. completion 2024-08-05 1 site Stand-alone
    Other conditions: Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC, Soft Tissue Sarcoma, Endometrial Cancer, Bladder Cancer
    View official trial listing →
  • Status unknown NCT NCT05670054

    Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients

    Not yet reported Mansoura University 116 participants Est. completion 2023-12-15 1 site
    Other conditions: Breast Cancer Stage IV
    View official trial listing →
  • Withdrawn NCT NCT05691400

    Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 Genotype

    Not yet reported University of Michigan Rogel Cancer Center Est. completion 2027-03 Stand-alone
    Other conditions: CYP3A4*22
    View official trial listing →
  • Active, not recruiting NCT NCT05694871

    Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

    Not yet reported Alliance for Clinical Trials in Oncology 77 participants Est. completion 2027-05-31 194 sites Stand-alone
    Obstructive sleep apnea Other conditions: Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
    View official trial listing →
  • Completed NCT NCT05709158

    A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)

    Pfizer 4184 participants Est. completion 2024-08-30 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT05759949

    First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

    Not yet reported Relay Therapeutics, Inc. 41 participants Est. completion 2025-04-11 7 sites Stand-alone
    Other conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Hormone Receptor Positive Tumor
    View official trial listing →
  • Active, not recruiting NCT NCT05826964

    Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

    Not yet reported University of Miami 24 participants Est. completion 2029-07-31 1 site Stand-alone
    Other conditions: Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT05865132

    Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

    Not yet reported AIPING ZHOU 30 participants Est. completion 2026-04 1 site Stand-alone
    Other conditions: Esophagus Squamous Cell Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05909397

    Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

    Not yet reported Pfizer 59 participants Est. completion 2026-12-30 29 sites Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT05912933

    A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)

    Pfizer 1342 participants Est. completion 2024-08-30 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT05935748

    Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

    Not yet reported NiKang Therapeutics, Inc. 18 participants Est. completion 2025-09-04 8 sites Stand-alone
    Other conditions: ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Carcinoma, Neoplasms, Carcinoma, Renal Cell, Neoplasms, Glandular and Epithelial, Neoplasm by Histology, Adenocarcinoma, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Kidney Diseases, Urologic Diseases
    View official trial listing →
  • Status unknown NCT NCT05949424

    OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults

    Not yet reported University Medical Center Groningen 30 participants Est. completion 2025-03 1 site Stand-alone
    Other conditions: Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma, Breast Carcinoma, Endometrium Carcinoma
    View official trial listing →
  • Completed NCT NCT05969184

    Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC

    Not yet reported Peking University Cancer Hospital & Institute 94 participants Est. completion 2026-06-25 2 sites
    Other conditions: Breast Neoplasm Female
    View official trial listing →
  • Completed NCT NCT06003114

    A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other Organs

    Pfizer 472 participants Est. completion 2024-02-22 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT06065592

    Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms

    Not yet reported Lebanese University 500 participants Est. completion 2024-12 2 sites Stand-alone
    Cardiovascular disease Other conditions: Cancer, Solid Tumor, Thromboembolism, Immune System Diseases, Inflammatory Diseases, Colon Cancer, Breast Cancer, Prostate Cancer, Hepatocellular Carcinoma, Lung Cancer, Chemotherapy, Immunotherapy
    View official trial listing →
  • Active, not recruiting NCT NCT06065748

    A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

    Not yet reported Hoffmann-La Roche 1050 participants Est. completion 2029-02-12 311 sites Stand-alone
    Other conditions: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT06076772

    Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients

    Assiut University 54 participants Est. completion 2026-12 1 site
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT06086340

    Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

    Pfizer 779 participants Est. completion 2024-01-24 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Terminated NCT NCT06126003

    Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

    BioCorteX Inc 2 participants Est. completion 2024-07-31 6 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT06307457

    A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.

    Pfizer 604 participants Est. completion 2024-04-19 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT06331715

    Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg

    Not yet reported Megalabs 24 participants Est. completion 2024-05-31 1 site Stand-alone
    Other conditions: Bioequivalence
    View official trial listing →
  • Status unknown NCT NCT06338644

    Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.

    Helwan University 100 participants Est. completion 2026-09-01
    Other conditions: Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer
    View official trial listing →
  • Status unknown NCT NCT06344780

    Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer

    Fudan University 200 participants Est. completion 2025-02-01 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT06367335

    Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer

    University of Milano Bicocca 128 participants Est. completion 2022-12-31 1 site
    Other conditions: DILI
    View official trial listing →
  • Active, not recruiting NCT NCT06390839

    Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

    Not yet reported National Cancer Institute (NCI) 43 participants Est. completion 2027-01-15 1 site Stand-alone
    Other conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
    View official trial listing →
  • Completed NCT NCT06463626

    Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study

    Novartis 121 participants Est. completion 2023-06-27 1 site
    Other conditions: Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
    View official trial listing →
  • Active, not recruiting NCT NCT06495164

    A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

    Pfizer 1 participants Est. completion 2026-12-30 1 site
    Other conditions: Breast Cancer, Malignant Neoplasm of Breast
    View official trial listing →
  • Completed NCT NCT06525675

    Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

    MedSIR 419 participants Est. completion 2024-09-02 36 sites
    Other conditions: Metastatic Breast Cancer, Advanced Breast Cancer, Luminal Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer
    View official trial listing →
  • Completed NCT NCT06570031

    ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

    Not yet reported Ono Pharmaceutical Co., Ltd. 46 participants Est. completion 2026-04-30 13 sites Stand-alone
    Other conditions: Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
    View official trial listing →
  • Completed NCT NCT06607601

    CARE Initiative: Real-world Emulation of the PALOMA-2 Trial

    Aetion, Inc. 724 participants Est. completion 2023-07-20
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Completed NCT NCT06624020

    A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in Australia

    Pfizer 1128 participants Est. completion 2024-07-31 1 site
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT06654297

    Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas

    Not yet reported West China Hospital 6 participants Est. completion 2027-02-07 1 site Stand-alone
    Other conditions: Esophageal Squamous Cell Carcinoma
    View official trial listing →
  • Not yet recruiting NCT NCT06692491

    Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

    Not yet reported Peking University Shenzhen Hospital 200 participants Est. completion 2029-12-31 Stand-alone
    Other conditions: Rare Tumour
    View official trial listing →
  • Not yet recruiting NCT NCT06757335

    A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer

    Not yet reported, Not yet reported Hinova Pharmaceuticals Inc. 204 participants Est. completion 2026-11-27 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06760637

    Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

    Not yet reported Pfizer 1035 participants Est. completion 2037-12-29 463 sites
    Other conditions: Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT06810492

    The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

    Not yet reported Hongmei Zheng, PhD 40 participants Est. completion 2027-12-01 Stand-alone
    Other conditions: Breast Cancer Stage III, Breast Cancer Stage II
    View official trial listing →
  • Not yet recruiting NCT NCT06941142

    A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

    Not yet reported CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 382 participants Est. completion 2028-06 Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT06962969

    A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

    Pfizer 1 participants Est. completion 2025-10-23 1 site
    Other conditions: Advanced or Metastatic Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07005557

    Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer

    Not yet reported Fudan University 1244 participants Est. completion 2035-05-15 Stand-alone
    Other conditions: Breast Cancer, Adjuvant Therapy
    View official trial listing →
  • Active, not recruiting NCT NCT07008508

    Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study

    Fondazione Policlinico Universitario Agostino Gemelli IRCCS 300 participants Est. completion 2032-05 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07061717

    Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

    Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 474 participants Est. completion 2029-07-01 1 site Stand-alone
    Other conditions: Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT07096024

    A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market

    Pfizer 95637 participants Est. completion 2025-02-07 1 site
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT07130643

    Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer

    Not yet reported Xinhong Wu, PhD 40 participants Est. completion 2027-06-20 1 site Stand-alone
    Other conditions: HR+/HER2- Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07173556

    A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer

    Not yet reported, Not yet reported Qilu Pharmaceutical Co., Ltd. 96 participants Est. completion 2028-10 Stand-alone
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Completed NCT NCT07178743

    Emulation of the PALOMA-2 Trial

    Brigham and Women's Hospital 6097 participants Est. completion 2026-03-01 1 site
    Other conditions: Advanced Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07191977

    Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma

    Not yet reported West China Hospital 41 participants Est. completion 2029-12 Stand-alone
    Other conditions: Esophageal Squamour Cell Cancer
    View official trial listing →
  • Completed NCT NCT07223476

    Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal

    Novartis Pharmaceuticals 1926 participants Est. completion 2024-07-01 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07299890

    An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

    Not yet reported Anhui Provincial Cancer Hospital 90 participants Est. completion 2027-11-01 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07300215

    An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast Cancer

    Not yet reported The First Affiliated Hospital of Bengbu Medical University 60 participants Est. completion 2027-11-01 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT07487129

    Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt

    Not yet reported Beni-Suef University 206 participants Est. completion 2025-12-20 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT07493291

    Effectiveness and Safety of Palbociclib: Brand vs. Generic in Iraqi Stage IV Breast Cancer Patients

    Al-Mustansiriyah University 100 participants Est. completion 2026-04-20 1 site
    Other conditions: Brest Cancer, CDK4/6 Inhibitor
    View official trial listing →
  • Completed NCT NCT07512063

    A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors

    Novartis Pharmaceuticals 480 participants Est. completion 2025-03-17 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07527806

    Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

    Not yet reported Peking University Cancer Hospital & Institute 156 participants Est. completion 2029-12-31 Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07683754

    T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

    Not yet reported Daiichi Sankyo 200 participants Est. completion 2030-08-28 Stand-alone
    Other conditions: Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive
    View official trial listing →
  • Not yet recruiting NCT NCT07687225

    Surgery vs. No Surgery for Primary Tumor in De Novo Stage IV Breast Cancer With Solitary Bone Metastases

    Not yet reported West China Hospital 216 participants Est. completion 2036-12-31
    Other conditions: Breast Cancer, Stage IV Breast Cancer, Bone Metastases
    View official trial listing →
  • Not yet recruiting NCT NCT07717450

    Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.

    Not yet reported UNICANCER 370 participants Est. completion 2032-06-25 Stand-alone
    Other conditions: Metastatic Invasive Breast Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07748208

    A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

    Not yet reported Hoffmann-La Roche 40 participants Est. completion 2029-09-30 Stand-alone
    Other conditions: Breast Cancer, Diabetes Type II
    View official trial listing →
  • Not yet recruiting NCT NCT07787520

    A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors

    Not yet reported Laekna Limited 150 participants Est. completion 2029-12 6 sites Stand-alone
    Other conditions: Patients With Advanced Solid Tumors
    View official trial listing →
  • Not yet recruiting NCT NCT07802626

    Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA Testing

    Not yet reported SWOG Cancer Research Network 1084 participants Est. completion 2035-10-30 Stand-alone
    Other conditions: HR Positive/HER-2 Negative Breast Cancer
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Palbociclib, Ibrance

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.